- Home
- AZ vs OTLK Comparison
AZ vs OTLK Comparison
Compare AZ & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZ | OTLK |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.6M | 249.6M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | AZ | OTLK |
|---|---|---|
| Price | $6.92 | $0.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $15.00 | $2.50 |
| AVG Volume (30 Days) | 553.8K | ★ 23.4M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | $532.60 | $1,430.98 |
| Revenue Next Year | $178.94 | $173.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.97 | $0.16 |
| 52 Week High | $9.82 | $2.54 |
Technical Indicators
Market Signals| Indicator | AZ | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 33.12 |
| Support Level | $6.57 | $0.19 |
| Resistance Level | $6.99 | $0.94 |
| Average True Range (ATR) | 0.59 | 0.09 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 41.09 | 9.86 |
Price Performance
Historical ComparisonAbout AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.